The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Subscribe To Our Newsletter & Stay Updated
